TendoNova Corp has raised $3.8M over 7 rounds; too few niche peers to rank its valuation yet.
Raised $3.8M across 7 disclosed rounds, last modeled as Recurring offerings.
Valued on the biotech profile — its sector's growth and survival benchmarks differ from the market default, so the same raise is worth more or less here.
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Latest round was 2.3× smaller than the prior — a bridge or down round.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Quiet
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Recurring offering issuermedium confidence
TendoNova Corp behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
Issuer structure
Program-like
Frequent filings and follow-ons read more like a securities offering program than discrete startup rounds.
Lifecycle
7.2 yr record
Peak capital year was 2019 with $6.3M across 8 filings.
Market position
ahead of 39% of Biotechnology peers
Capital scale is ahead of 39% of Biotechnology peers; modeled value is above 4% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Lower applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
21 dated financing filings, averaging about 3 months apart.
No clearly named CEO/founder/principal role in the public records surfaced here.
No verified homepage on the profile yet.
Capital program peaked in 2019: $6.3M across 8 filings.
Largest single filing was $1.4M on 2019-04-04.
Filing rows sum to $11.1M, while canonical raised total is $3.8M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
Read this less like a startup funding journey and more like a capital-raising program.
Stage-based valuation and peer labels have lower applicability for this pattern.
The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Canonical filtering should be tightened before using row-level totals for diligence.
Leadership
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Where it sits in Biotechnology
TendoNova Corp is one of 4291 Biotechnology companies tracked from Atlanta. By capital raised it ranks in the long tail (ahead of 39% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2024-06-26
First sale
Amount raised vs valuation, by year
This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.
Annual capital raised · realLatest value in year · estCumulative funded · real
Dense history compressed: 21 filings shown as 5 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Financing ladder & sequence gaps
This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.
Initial offering$860K · 2019
Follow-on offering$835K · 2019
Follow-on offering$325K · 2019
Follow-on offering$335K · 2019
Follow-on offering$1.1M · 2019
Follow-on offering$1.3M · 2019
Follow-on offering$1.4M · 2019
Follow-on offering$200K · 2019
Follow-on offering$300K · 2021
Follow-on offering$170K · 2021
Follow-on offering$446K · 2021
Follow-on offering$160K · 2022
Follow-on offering$215K · 2022
Follow-on offering$440K · 2022
Follow-on offering$225K · 2023
Follow-on offering$300K · 2023
Follow-on offering$250K · 2023
Follow-on offering$602K · 2024
Follow-on offering$762K · 2024
Follow-on offering$627K · 2024
Follow-on offering$270K · 2024
Modeled valuation trajectory
$1.3M
Base estimate est.
$194K
Conservative case
$3.5M
Upside case
$1.4M
Modeled post-money
This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
$736K/yr
Capital velocity
7.2 yr
On record since
2019
First round
21
Rounds on file
How it compares to the market
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Total raised — vs sector median (real $, all stages)▼ 0.5× of median
This company$3.8M
Sector median$7.2M
Modeled value — vs sector median (estimate, all stages)▼ 0.0× of median
This company$1.3M
Sector median$64.2M
Raised more than 39% of sector peers (real $). Modeled value above 4% of peers (estimate).
Full financing history
This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.
Stage
Amount · real
Announced
Post-money · est
Value · est
Conf.
Initial offering
$860K
2019-04-04
$4.8M
$47.5M
90%
Follow-on offering
$835K
2019-04-04
$4.6M
$46.1M
90%
Follow-on offering
$325K
2019-04-04
$1.8M
$17.9M
90%
Follow-on offering
$335K
2019-04-04
$1.9M
$18.5M
90%
Follow-on offering
$1.1M
2019-04-04
$5.3M
$47.1M
90%
Follow-on offering
$1.3M
2019-04-04
$6.6M
$59.0M
90%
Follow-on offering
$1.4M
2019-04-04
$6.9M
$61.2M
90%
Follow-on offering
$200K
2019-04-04
$1.1M
$11.0M
90%
Follow-on offering
$300K
2021-09-22
$1.7M
$7.7M
90%
Follow-on offering
$170K
2021-09-22
$944K
$4.4M
90%
Follow-on offering
$446K
2021-09-22
$2.2M
$10.0M
90%
Follow-on offering
$160K
2022-07-29
$889K
$2.4M
90%
Follow-on offering
$215K
2022-07-29
$1.2M
$3.3M
90%
Follow-on offering
$440K
2022-07-29
$2.2M
$6.2M
90%
Follow-on offering
$225K
2023-07-17
$1.3M
$1.9M
90%
Follow-on offering
$300K
2023-07-17
$1.5M
$2.5M
90%
Follow-on offering
$250K
2023-11-01
$1.3M
$1.7M
90%
Follow-on offering
$602K
2024-02-15
$3.3M
$3.5M
90%
Follow-on offering
$762K
2024-02-15
$3.8M
$4.5M
90%
Follow-on offering
$627K
2024-02-15
$3.5M
$3.6M
90%
Follow-on offering
$270K
2024-06-26
$1.4M
$1.3M
90%
What happened at each round
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Initial offering$860K2019-04-04
First recorded raise — entered as Initial offering.
6 investors on this round.
Follow-on offering$835K2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
5 investors on this round.
Follow-on offering$325K2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.6× smaller than the prior — bridge or down round.
3 investors on this round.
Follow-on offering$335K2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
4 investors on this round.
Follow-on offering$1.1M2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 3.2× larger than the prior — scaling up.
7 investors on this round.
Follow-on offering$1.3M2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
11 investors on this round.
Follow-on offering$1.4M2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
13 investors on this round.
Follow-on offering$200K2019-04-04
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 6.9× smaller than the prior — bridge or down round.
2 investors on this round.
Follow-on offering$300K2021-09-22
Raised again after 30 mo — slower than the ~14 mo sector norm.
Round 1.5× larger than the prior — scaling up.
9 investors on this round.
Follow-on offering$170K2021-09-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.8× smaller than the prior — bridge or down round.
3 investors on this round.
Follow-on offering$446K2021-09-22
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.6× larger than the prior — scaling up.
11 investors on this round.
Follow-on offering$160K2022-07-29
Raised 10 mo later, in step with the ~14 mo sector norm.
Round 2.8× smaller than the prior — bridge or down round.
4 investors on this round.
Follow-on offering$215K2022-07-29
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.3× larger than the prior — scaling up.
6 investors on this round.
Follow-on offering$440K2022-07-29
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 2.0× larger than the prior — scaling up.
8 investors on this round.
Follow-on offering$225K2023-07-17
Raised 12 mo later, in step with the ~14 mo sector norm.
Round 2.0× smaller than the prior — bridge or down round.
2 investors on this round.
Follow-on offering$300K2023-07-17
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round 1.3× larger than the prior — scaling up.
3 investors on this round.
Follow-on offering$250K2023-11-01
Came back fast: 4 mo vs the ~14 mo sector norm.
Round roughly the size of the prior one.
10 investors on this round.
Follow-on offering$602K2024-02-15
Came back fast: 3 mo vs the ~14 mo sector norm.
Round 2.4× larger than the prior — scaling up.
4 investors on this round.
Follow-on offering$762K2024-02-15
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
6 investors on this round.
Follow-on offering$627K2024-02-15
Filed alongside the prior round (same month) — likely a tranche or amendment.
Round roughly the size of the prior one.
5 investors on this round.
Follow-on offering$270K2024-06-26
Came back fast: 4 mo vs the ~14 mo sector norm.
Round 2.3× smaller than the prior — bridge or down round.
3 investors on this round.
Intelligence
2024 ~Q3
Modeled next raise · ~3mo cadence
$270K
Modeled next size est.range $270K–$432K
0.4×
Last step-up
$736K/yr
Capital velocity
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Key people & operators
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
TendoNova Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
United States
Country of record
US
Jurisdiction
1774275
SEC CIK
Similar companies
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
TendoNova Corp has raised approximately $3.8M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is TendoNova Corp's estimated valuation?
Provath's modeled valuation for TendoNova Corp is approximately $1.3M (modeled range $194K–$3.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is TendoNova Corp at?
TendoNova Corp shows a recurring offering pattern rather than a clean VC stage progression. Its most recent recorded round closed around Wed Jun 26.
What does TendoNova Corp do and where is it based?
TendoNova Corp operates in the Biotechnology sector, based in Atlanta.
Explore related
See where TendoNova Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at TendoNova Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.